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Recent reports on direct reprogramming of cancer cells (iPCs) which results in reduced tumorigenic
potential has attributed the importance of epigenetics in tumorigenesis, but lacked genome-wide analysis.
Here we describe successful generation of iPCs from non-small cell lung cancer (NSCLC) cell lines.
Following reprogramming, they resembled embryonic stem and induced pluripotent stem cells in
pluripotency markers expression, gene expression patterns and in vitro differentiation ability.
Genome-wide methylation analysis revealed that aberrantly methylated promoters which were mostly
developmental-associated genes and tumor suppressors; as well as commonly upregulated genes in NSCLC
i.e. KRT19 and S100P were reversed in iPCs upon reprogramming. Also, the reversal of oncogenes and
tumor suppressors status were partially explainable by DNAmethylation. These findings suggest that DNA
methylation patterns explain the downstream transcriptional effects, which potentially caused the reduced
tumorigenicity in iPCs, thus providing evidence that reprogramming reverses the aberrantly dysregulated
genes in NSCLC both epigenetically and transcriptionally.
L
ung neoplasm has been documented as the leading cause of death by cancer amongst men and second
amongst women consistently1. Neoplasia is widely thought to be driven by genomic instability which is due to
both reversible and irreversible alterations2. The epigenetic alterations primarily constitute the former while
genetic mutations constitute the latter. Epigenetics which largely regulate gene expression can result in either the
aberrant silencing of tumor suppressors or upregulation of oncogenes thereby contributing to tumorigenesis3. On
the other hand, somatic gene mutations may result in additional functional consequences, apart from gene
expression regulation which eventually promotes genomic instability4. It is currently thought that a handful of
spurious mutations is both necessary and sufficient to cause malignant transformation5. Another form of genetic
mutation involves irreversible chromosomal insults as demonstrated by the classic experiment performed by
Theodor Boveri on sea urchin eggs6, consistent with the observation that Down syndrome patients suffer from
higher incidence of cancer7. Chromosomal damage or aneuploidy indeed affects thousands of genes and disturbs
the stoichiometry of the cell, resulting in dysregulation of cell functions which eventually leads to cancer8.
Indeed, if cancer is a genetic disease by virtue of somatic mutations, it would be of interest to elucidate whether
recapitulation of the cancer phenotype is achievable with direct reprogramming9,10 as has been shown with
familial diseases11,12. However, several groups have recently reported that reprogrammed cancer cells are less
tumorigenic compared to the parent cancer cell13–15, suggesting that epigenetics are pertinent in cancer progres-
sion. However, a genome-wide analysis is still lacking.We therefore hypothesized that direct reprogrammingmay
have reversed the aberrant epigenetic alterations in cancer cells which are important in cancer progression. To
this end, we embarked on a study involving genome-wide analyses of DNA methylation and gene expression
patterns of induced pluripotent cancer cells (iPC). Here, we describe the successful reprogramming of non-small
cell lung cancer (NSCLC) i.e. H358 and H460. We found that colonies derived from H358 (iPCH358) and H460
(iPCH460) were morphologically indistinguishable from the reprogrammed IMR90 (iPSIMR90) and embryonic
stem cells (ES), i.e. H1 and HES-3. iPC were pluripotent as demonstrated by presence of ES cell markers and
ability to differentiate into three germ layers in vitro. Furthermore, the reprogrammed cells shared similar gene
expression patterns with H1. In addition, key NSCLC biomarkers such as aberrantly methylated promoters
(AMPs) and important prognostic factors were also reversed in iPC and this was followed through in the in
vitro differentiated iPC (post-iPC) cells. In parallel to the downregulation of pro-angiogenic oncogenes (OGs), we
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evidence that direct reprogramming amends the aberrant epigenetic
signatures of cancer cells whichmay contribute to abrogation of their
malignant properties.
Results
Generation of iPC from NSCLC lines. Reprogramming of cancer
cells appears to be challenging due to various genetic alterations
including aberrant gene silencing in cancers which may interfere
with the process. Here, we show that two NSCLC cell lines i.e.
H358, an adenocarcinoma, and H460, a large cell carcinoma, were
successfully reprogrammed following the forced expression of
Yamanaka’s four transcription factors i.e. OCT3/4, KLF4, c-MYC
and SOX29. As controls for the reprogramming experiment as well
as reference to the NSCLC cell lines, we reprogrammed IMR90, a
human fetal lung fibroblast, using the same factors and obtained
iPS colonies. Our results showed that IMR90 was more readily
reprogrammed compared to the two NSCLC cell lines as the
former formed ES-like colonies at day-8 post-infection, before the
cells were seeded onto feeder cells (Fig. 1a). The latter however,
showed clusters of cells that were irregular but upon seeding onto
feeder cells at day 15 post-infection, we found that themorphology of
these colonies were identical to the colonies obtained from IMR90 as
well as H1 and HES-3 (Fig. 1a,b).
Morphologically and transcriptionally indistinguishable to H1.
Upon obtaining the ES-like colonies, we evaluated their pluri-
potency status following alkaline phosphatase (AP) staining. Our
colonies derived from H358 and H460 cancer cells showed positive
for AP activity and stained purple similar to iPSIMR90 and H1
(Fig. 1b). Immunofluorescence data further confirmed that these
colonies expressed ES cell markers, as they all stained positive for
TRA-1-60 and Nanog (Fig. 1b). Real-time PCR (qPCR) results
showed that the iPCs expressed pluripotency markers such as
SOX2, NANOG, FGF4, and OCT3/4 at levels comparable to iPS
cells (Fig. 1c). Moreover, all colonies depicted higher telomerase acti-
vity (TA) as compared to their respective parental cells (Fig. 1d). In
addition, our global gene expression analysis also revealed that iPC,
post-iPC (piPC), iPS and H1 were clustered together, indicating
similarity in their gene expression profile (Fig. 2a,c). On the other
hand, data from methylation array indicated that iPC, piPC and iPS
have similar methylation profiles, but differed from H1 (Fig. 2b,c).
We attribute this difference to the early passage of iPS and iPC
(passage 4–8) used in this array16,17. Nonetheless, since gene expres-
sion is downstream of DNA methylation regulation, we postulated
that the deviation of iPS and iPC from H1 in methylation profile
is non-consequential in pluripotency maintenance, as the gene
expression patterns showed that the reprogrammed cells did not
diverge largely from H1. However, it is possible that the generated
iPS and iPC have restricted commitment lineages18. In addition, gene
ontology (GO) analysis of hypomethylated promoters in iPC
compared to their respective cancer parents showed enrichment of
developmental associated genes (Fig. 2d).
Spontaneous in vitro differentiation of iPC. In order to assess the
differentiation ability of the reprogrammed cells, embryoid bodies
(EBs) were formed in vitro and transferred to gelatin-coated plates to
generate post-iPS (piPS) or piPC (Fig. 3a). Our data provides evi-
dence that, like iPS, iPC cells derived from lung cancer have the
ability to differentiate into the three germ layers in vitro.When com-
pared to their respective parental cells, the EBs, piPS and piPC cells
revealed up-regulation in ectoderm markers i.e CDX2 and PAX6,
genes that identify mesoderm layer i.e Brachyury and MSX1, as
well as endoderm genes such as GATA4 and FOXA2 (Fig. 3b).
Direct reprogramming hypomethylates AMPs in NSCLC. We
next, went on to investigate if reversible alterations in cancer cells
were reverted upon reprogramming. To address this, we first
generated a list of known AMPs in NSCLC through literature
search (Table S1). We found 237 unique AMPs, out of which, 217
were interrogated by Illumina Infinium Human Methylation 27 k
BeadChip array. Indeed, these genes were over-represented among
all methylated promoters in H358 and H460 lung cancer cells but
under-represented among all methylated promoters in IMR90 nor-
mal lung fibroblasts (Fig. 4a).We first categorized the promoters that
are aberrantly hypermethylated in NSCLC by comparing them to
IMR90.We found 105 and 94AMPs inH358 andH460, respectively,
and 84AMPswere shared betweenH358 andH460 (Fig. 4a). Interes-
tingly, we observed that 71 (67.6%) and 50 (53.2%) of the AMPs in
H358 and H460 respectively became hypomethylated upon repro-
gramming (Fig. 4b). Among them, 44 promoters overlapped, many
of which represent developmental associated genes such asHOX and
PAX gene clusters, as well as tumor suppressors such asAPC, TIMP3
andWRN (Fig. 4b, Table S2). Methylation-specific PCR (MSP) also
verified this observation. APC along with HOXA5, HOXA7, HOXC9
and HOXD13 were all hypomethylated in iPC colonies (Fig. 4c).
Bisulfite genomic sequencing was used to evaluate and quantify the
methylation level at every cytosine-guanosine dinucleotides (CpGs)
contained within the amplified sequence. Results revealed that the
CpGs of HOXA5 were not methylated appreciably in iPC cells as
compared to their parent cancer cells (Fig. S1a). We therefore
showed evidence that aberrant DNA methylation in cancer was
reversed by direct reprogramming.
We then asked whether the hypomethylated AMPs translate into
gene upregulation. Here, we showed that 25 (35.2%) and 13 (26%) of
the hypomethylated AMPs resulted in adjacent gene upregulation
($ 2-fold change, false discovery rate (FDR)# 0.05) in iPCH358 and
iPCH460, respectively (Fig. 4d,e). The remaining genes did not
change in transcript levels. The latter observation is explainable by
the fact that promoter hypomethylation does not necessarily result in
gene upregulation concurrently, but has the potential to cause upre-
gulation subsequently19,20. Our qPCR results concurred with gene ex-
pression array data. Transcription of Homeobox genes i.e. HOXA5,
HOXA7 and HOXD13 were significantly upregulated in all iPC col-
onies when compared to respective cancer cells (Fig. 4f). RPRM, a
gene known to be heavily methylated in lung cancer and its low
expression correlated with poor prognosis21 was also restored upon
reprogramming, consistent with the hypomethylation observed
(Fig. 4c,f).
Downregulation of NSCLC biomarkers upon reprogramming.
We then assessed if the genes commonly upregulated in NSCLC
(UR), would be downregulated upon reprogramming. Similar to
AMPs, we generated a list of URs based on literature and pub-
lished gene expression data of NSCLC clinical samples deposited
in GEO database (GSE19188)22 (Table S3). In our list of 420 uni-
que genes, 391 genes were interrogated in the Illumina HumanHT-
12 array. From this master list, we identified 110 and 59 genes to be
upregulated ($ 2-fold change, FDR # 0.05) in H358 and H460,
respectively, when compared to IMR90 and we define these genes
as URs in our cancer samples. Among these, 52 (47.3%) and 25
(42.4%) were downregulated in iPCH358 and iPCH460, respec-
tively, and were over-represented for genes downregulated upon
reprogramming (Fig. 5a, Table S4).
The URs that were downregulated in H358 and H460 upon repro-
gramming include important prognostic factors such asKRT19 (also
known as CK19 or CYFRA 21-1), S100P, KRT7, PPAP2C and
AGR223–27. Our validation with qPCR concurred with the gene
expression array data (Fig. 5b). Interestingly, URs that were down-
regulated upon reprogramming can be explained by DNA hyper-
methylation in iPCs (Fig. 5c). This was further confirmed for
S100P and KRT19 genes in which MSP and qPCR results showed
complete methylation and gene silencing respectively, in all iPC
colonies as compared to the parental cancer cells (Fig. 5c,d). The
www.nature.com/scientificreports
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methylation status in iPC cells was further quantified using bisulfite
sequencing. H358iPC and H460iPC cells were highly methylated in
KRT19 gene withmethylation scores 86% and 96%, respectively (Fig.
S1b). This suggests that epigenetics, largely DNA methylation,
played a role in the dysregulation of URs to cause malignant trans-
formation. To rule out any possibility that the remaining URs main-
tained a high transcript level in iPCs, we therefore checked whether
these transcript levels were comparable to H1. To our surprise, we
Figure 1 | Generation and characterization of iPC from NSCLC lines. (a) Morphology of parental IMR90 fibroblasts, H358 and H460 cancer cells.
Formation of ES-like colonies in IMR90, H358 and H460 cells on day 8 post-infection of four factors. Upon seeding onto feeder layer on day 15 post-
infection, iPS and iPCs formed flat and round edged colonies like (b) ES cells i.e. H1 and HES-3. Similar to H1, iPSIMR90, iPCH358 and iPCH460
colonies stained positive for AP. Representative images of individual colonies derived from IMR90, H358 and H460 showed positive staining for
pluripotency markers i.e. TRA-1-60 (green) and Nanog (red) respectively. Nuclei were stained with Hoechst 33342 (blue). Scale bars: 20 - 500mm. (c) iPS
and iPC expressed high levels of ES cell markers namely SOX2,NANOG, FGF4 andOCT3/4 as compared to their parental cells. ThemRNA expression was
normalized to GAPDH mRNA expression. (d) iPS and iPC depicted higher TA when compared to their respective parental cells. Data are presented as
mean 6 SD.
www.nature.com/scientificreports
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did not find any evidence to reject the null hypothesis. Therefore, it is
likely that these URs were required at high expression levels to main-
tain the iPCs in an ES-like state. Nonetheless, we have shown that
reprogramming indeed reverses the aberrantly upregulated genes in
NSCLC both epigenetically as well as transcriptionally.
Oncogenes and tumor suppressors. In order to compare the gene
regulation of tumor suppressors (TS) and oncogenes (OG) in our
experiment, firstly, we obtained a list of TS and OG from the
Memorial Sloan-Kettering Cancer Center Database (cbio.mskcc.org/
CancerGenes; accessed on 5 Dec 2011)28 and determined the aberrant
regulation of these genes in H358 and H460 as compared to IMR90
cells.
Among the 495 OG obtained from the database, we identified
42 and 29 genes that were aberrantly upregulated in H358 and
H460, respectively. Among these, 25 (59.5%) and 14 (48.3%) were
Figure 2 | Genome-wide assessment of gene expression and CpG methylation profiles of iPC derived from lung cancer. (a) Hierarchical clustering
showing gene expression patterns of the parents, iPCs, post-iPCH358 (piPCH358), iPS and H1. (b) Clustering of samples based on methylation levels of
the parents, iPCs, iPS, piPCH358, post-iPCH460 (piPCH460) andH1. (c) Paired scatter plot illustrating the similarities of gene expression levels between
iPS/Cs and H1 (Blue). Methylation levels, on the other hand, were only similar between iPS and iPC but differed from H1 (Red). (d) GO analysis of
hypomethylated promoters in iPC compared to cancer parents showing enrichment in developmental associated genes.
www.nature.com/scientificreports
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downregulated upon reprogramming (Fig. 6a). We found that the
gene expression patterns in H358 and iPCH358 were satisfactorily
explained by DNA methylation, whereby DNA hypomethylation in
H358 attributed to OG aberrant upregulation and DNA hyper-
methylation in iPCH358 silenced these aberrantly upregulated genes
(Fig. 6b, Table S5). However, this trend is not statistically significant
for H460 and iPCH460 (Fig. 6b, Table S5) and we speculate that
other gene regulation mechanisms were utilized in these cells.
Nonetheless, the top three oncogenes which were upregulated in
both the cancer cell lines i.e. EFNA1, CXCL1 and CXCL2 were pro-
angiogenic factors29–31 which became downregulated upon repro-
gramming in all iPC and piPC cells (Table S5). ID1, an oncogene
that promotes lung cancer cell proliferation32 was also observed to be
downregulated in the reprogrammed NSCLC line.
As for TS, we obtained 873 genes from the database. From this
list, approximately 87 and 74 TS were aberrantly downregulated in
H358 and H460, respectively, when compared to IMR90. We
found that 21 and 6 of these TS were significantly upregulated
upon reprogramming (Fig. 6c). Of these, TSs CADM133 and
PLAGL134 were transcriptionally elevated in both reprogrammed
H358 and H460 cell lines as compared to their respective parental
cells. Nonetheless, we noted that the total percentage of TS upre-
gulation were low and found that the large, remaining bulk of
these genes also have comparably low expression levels in H1
(Table S6), suggesting that TS genes possibly need to be main-
tained at low levels for cell proliferation and survival35. Following
this, we investigated whether DNA methylation could explain the
regulation of these TS. We observed that the promoters of TS were
significantly hypermethylated in H358 and hypomethylated in
iPCH358, but the same observation was not detected in H460
and iPCH460 (Fig. 6d). We concluded that the dysregulation of
oncogenes (OGs) and tumor suppressors (TSs) in NSCLC were
reversed upon reprogramming and were partially explainable by
intricate DNA methylation regulation.
Discussion
The reprogramming of cancer cells have been reported in mice mel-
anoma15,36, human melanoma, prostate cancer37, chronic myeloid
leukemia38, a panel of gastrointestinal cancer cells14, lung39 and breast
cancer cells13. Here we describe the successful reprogramming of
NSCLC cell lines, namely H358 and H460. The evidence for
pluripotency in iPCH358 and iPCH460 were manifested through
AP staining, pluripotency markers expression and in vitro differenti-
ation assay by EBs formation which exhibited the presence of mar-
kers that identify the three germ layers.Moreover, we also present the
first extensive characterization of the methylome and transcriptome
of iPS and iPC through DNAmicroarray technologies. Although our
methylation data may be affected by epigenetic memory of early
passages of iPS and iPC, this did not affect its downstream regulation
of the transcriptomes. Indeed, the transcriptome of iPS, iPC and
piPCwere indistinguishable from each other and were closely related
to ES cells. This observation is indeed novel and reveals that can-
cer cells can be reprogrammed to attain ES-like characteristics.
Motivated by this, we assessed the reversible changes that account
for tumorigenesis such as aberrant hypermethylation of promoters as
well as abnormal upregulation of genes in NSCLC. Furthermore, we
also investigated the fate of oncogenes and tumor suppressors in our
cancer cell lines upon reprogramming.
Previously, Ron-Bigger et al. (2010) reported that reprogram-
ming could reverse hypermethylated promoters, particularly
tumor suppressor gene p16 in hTERT immortalized human lung
fibroblast (WI-38), however the established subclone of hTERT
cells may not be entirely similar to cancer cells40. In our study, we
have reprogrammed established cancer cell lines to satisfactorily
address the question whether direct reprogramming may reverse
AMPs in cancer. Considering that DNA hypermethylation is
associated with silencing of gene transcription19, these aberrantly
hypermethylated promoters, which are largely enriched for differ-
entiation-associated genes in lung cancer41, possibly confer growth
advantages to cancer cells. Our study showed that direct repro-
gramming were able to perturb the epigenetics of lung cancer cells
by causing the reversal of these AMPs and in some instances,
resulted in active gene transcription. However, it is interesting
to note that despite using early passages of iPCs to assess this
question, which has been shown to cause interference due to
epigenetic memory from the parental cells, we were still successful
in proving this point16,17. Indeed, it is very plausible that our data
is underestimated. It was reported previously that genes expressed
in fully differentiated lung cells are repressed in lung cancer and
vice versa42,43 and was explainable by DNA methylation41. It was
Figure 3 | In vitro differentiation of iPC cells through EB formation. (a) Generation of EBs and piPCs cells. EBs weremaintained as floating culture for 8
days before returning to adherent culture for another 8 days. Scale bars, 200 mmor 500 mm. (b) qPCR results demonstrated that EBs and piPC fromH358
and H460 expressed markers of the three embryonic germ layer i.e. CDX2 and PAX6, (ectoderm), Brachyury andMSX1 (mesoderm), and GATA4 and
FOXA2 (endoderm). The mRNA expression was normalized to GAPDH mRNA expression. Data are presented as mean 6 SD.
www.nature.com/scientificreports
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suggested that this observation possibly implies that lung cancer
development is related to a dedifferentiation event and exactly
how it confers growth advantage to result in malignancy remains
unclear. Nonetheless, our study shows that following reprogram-
ming, the iPCs no longer harbor the same aberrant DNA methy-
lation mark and may no longer exhibit malignancy.
Figure 4 | Fate of AMPs upon direct reprogramming of lung cancer cells. (a) Table and Venn diagram showing the number of identified AMPs
methylated in H358, H460 and IMR90. P-value and odds ratio (OR) was calculated using Fisher’s exact test against the expected background; OR.1:
over-representation, OR,1: under-representation. (b) Table and Venn diagram illustrating the number of identified AMPs that are hypomethylated in
iPCH358 and iPCH460. Fisher’s exact test was used to calculate P-value and OR. (c) MSP analyses further verified the methylation status of AMP genes
extracted from the array. (d) Heat map representing all hypomethylated AMPs identified in (b). Methylation pattern is depicted in green (unmethylated)
and red (methylated). Adjacently, the gene expression patterns showed here in yellow (downregulated) and blue (upregulated) illustrate gene
upregulation in iPCs upon hypomethylation. (e) Quantification of the number of genes upregulated, downregulated or status quo among all
hypomethylated AMPs in iPCH358 and iPCH460. (f) qPCR on HOX gene clusters and other AMPs corroborated with the gene expression data. The
mRNA expression was normalized to GAPDH mRNA expression. Data are presented as mean 6 SD.
www.nature.com/scientificreports
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Another reversible alteration we observed inNSCLCwas the com-
monly upregulated genes. Since the advent of DNAmicroarray tech-
nologies to interrogate mRNA transcript levels, assays have been
performed to identify biomarkers to predict lung cancer survival
in patients22,44,45. By compiling a list of genes that are commonly
upregulated in NSCLC compared to normal adjacent tissue, we
report that these markers that are found to be aberrantly upregulated
in H358 or H460 were subsequently downregulated upon repro-
gramming. And this list includes important prognostic factors of
lung cancer such as KRT19 and S100P23,24. Moreover, our array data
revealed that the regulation of these genes can be satisfactorily
explained by DNA methylation. Therefore, it is interesting to note
that these markers are made absent upon induction of pluripotency.
Again, supposing that these prognostic factors are pertinent in can-
cer progression46,47, we find that direct reprogramming may result in
loss of malignancy. We, therefore present evidence here that epige-
netic changes were significant in explaining the regulation of these
genes and hence the importance of epigenetics in NSCLC progres-
sion. Indeed, the observed results are fascinating in that the
prognostic factors as well as DNA methylation markers that are
crucial for NSCLC progression seem to be reversed upon direct
reprogramming. However, this observation does not discount the
possibility of reacquiring these phenotypes upon directed differenti-
ation to lung lineage cells. Unfortunately to date, there are no estab-
lished protocols for directed differentiation to lung lineage cells.
Nonetheless, we assessed whether these cancer markers manifested
in the in vitro differentiated piPC cells. To our surprise, we did not
find any aberrant dysregulation of these genes as well as DNAmethy-
lationmarkers and we conclude that direct reprogramming of cancer
cells resulted in the reversion to normal DNA methylation and gene
expression regulation (Table S4).
We further analyzed the effect of direct reprogramming on a panel
of TSs and OGs. Surprisingly, we found that these genes i.e. pro-
angiogenic factors such as EFNA1, CXCL1 and CXCL2 as well as ID1
which work in concert to promote tumorigenesis were reversed to the
normal expression levels in iPC and remained so in piPC (Table
S5,S6). On the other hand, TSs such as CADM1 and PLAGL1 were
upregulated in the NSCLC lines upon reprogramming. Interestingly,
we found that the regulation of these genes in H358 were promi-
nently explainable by DNAmethylation but not in H460. This reveals
Figure 5 | Aberrantly upregulated URs were reversed upon direct reprogramming of NSCLC cell lines. (a) Identified URs that were downregulated in
iPCs were over-represented in all downregulated genes in iPC compared to parents. Fisher’s exact test was conducted to determine the OR
(.1:over-representation) and P-value. Number of genes shared between iPCH358 and iPCH460were illustrated in the Venn diagram. (b) qPCR showing
downregulation of UR genes in iPCH358 and iPCH460 that were initially upregulated in the parental cancer cells. ThemRNA expression was normalized
to GAPDHmRNA expression. Data are presented as mean 6 SD. (c) Heat map illustrating the downregulation of URs in iPCs as a consequence to DNA
hypermethylation. (d) MSP analyses on KRT19 and S100P showing consistent data with the methylation array.
www.nature.com/scientificreports
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that the mechanism behind aberrant dysregulation of tumor suppres-
sors and oncogenes are more robust and may include other mechan-
isms such as gene deletions and gene amplifications, to name a few.
Our extensive study has revealed a better understanding of cancer.
In the wisdom of Thomas S. Kuhn, in his landmark thesis on para-
digms48, direct reprogramming is indeed a new tool to study and
understand cancer cells, which may result in paradigm shifts. By
globally resetting the epigenetic state of lung cancer cells through
direct reprogramming, our study provides evidence that these cells
may become reticent by reversing aberrant epigenetic changes in
NSCLC which in turn affects the gene regulation. However, it is of
interest to study whether the directed differentiation of these iPCs to
different commitment lineage will result in malignant manifestation
phenotypically as well as epigenetically, although, our in vitro differ-
entiation assay suggests that this may not be true.
Reversal of aberrant cancer methylome, which explains regulation
of prognostic factors as well, by direct reprogramming provides
evidence that DNA methylation is important for tumorigenesis. By
extension, targeting epigenetics factors to inhibit tumor growth as
shown clinically49, is the way forward. Epigenetic based therapy by
itself or in combination with current available drugs for NSCLCmay
be an improved and better therapeutic regimen for lung cancer
patients in the near future. However, development of drugs with
higher degree of precision and targeting will be desired. It would
be of interest to elucidate the indirect roles of Yamanaka’s four fac-
tors in the delicate regulation of epigenetics in a cell, i.e. hypomethy-
lation or hypermethylation at specific loci. Better understanding of
this mechanism would certainly contribute to a more sophisticated
and effective treatment of cancer than currently tested non-specific
DNA methylation inhibitors or DNA demethylating agents.
Methods
Cell lines and culture conditions. Cell lines used in our study include human
embryonic lung fibroblasts IMR90 (ATCC no. CCL-186), NSCLC lines i.e.
adenocarcinoma NCI-H358 (ATCC no. CRL-5807) and large cell carcinoma NCI-
H460 (ATCC no. HTB-177), as well as ES cells i.e. H1 and HES-3. All cell lines were
maintained as recommended by the American Type Culture Collection (ATCC). iPS,
iPC and ES cells on the other hand, were cultured and expanded on irradiated mouse
embryonic fibroblasts (iMEFs) in medium consisting of DMEM/F12 (Invitrogen),
20% Knockout Serum Replacement (Invitrogen), 1 mM L-glutamine (Invitrogen),
100 mM nonessential amino acids, 100 mM b-mercaptoethanol (Sigma-Aldrich), and
supplemented with 4 ng/uL basic fibroblast growth factor (bFGF) (Invitrogen).
Pluripotent cells on Matrigel (BD Biosciences) were maintained using mTeSH1
(STEMCELL Technologies) medium.
Transfection and infection. Human iPC and iPS cells were established using
Yamanaka’s protocol with slight modification9. Infectious lentiviral particles were
produced by transfecting 293T cells with pLenti6/UbC/mSlc7a1 (Addgene plasmid
17224) using Lipofectamine. Retroviral vectors (pMXs) used in this study include of
pMXs-hOCT3/4 (Addgene plasmid 17217), pMXs-hSOX2 (Addgene plasmid
17218), pMXs-hKLF4 (Addgene plasmid 17219) and pMXs-hC-MYC (Addgene
plasmid 17220). The viral transfectants were collected, mixed and filtered before
infecting human fibroblasts and cancer cells. Individual ES-like colonies were picked
and passaged on six-well plates on iMEFs and maintained in hES medium.
RNA isolation, reverse transcription and qPCR. Total RNA was extracted by using
RNeasy Mini Kit (Qiagen) and reverse-transcribed using Reverse Transcriptase
Enzyme (Promega) as well as oligo dT primers (Promega), according to
manufacturer’s instruction. The synthesized cDNA was diluted and SYBR Green
Figure 6 | The fate of oncogenes (OG) and tumor suppressors (TS) following direct reprogramming of lung cancer cells. (a) Identified OG in parental
cancer cells were downregulated upon direct reprogramming and were over-represented among all downregulated genes (OR.1:over-representation).
(b) Heat map illustrating DNA methylation controls the gene expression changes of OG in H358 upon direct reprogramming, but not in H460.
(c) Similarly, identified TS were upregulated in cancer iPCs upon direct reprogramming. (d) Heat map illustrating hypomethylation of promoters in
iPCH358 on adjacent upregulated TS, but not so in iPCH460.
www.nature.com/scientificreports
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qPCR Master Mix (Applied Biosystems) was used for the detection. Relative
expression was calculated using the DDCt method. All samples were performed in
duplicates and error bars represent standard deviation of the relative values. GAPDH
housekeeping gene was set as the reference. Primers used in qPCR are shown in
Table S7.
Alkaline phosphatase (AP) staining. AP staining was performed using the Alkaline
Phosphatase Detection Kit (Millipore), in accordance with the manufacturer’s
instruction.
Telomerase activity (TA) assay. TA was quantified using TeloExpress Quantitative
Telomerase Detection Kit (ExpressBio) which utilizes the telomerase repeat
amplification protocol (TRAP)-based qPCR method, according to the
manufacturer’s instruction. TA in each sample was calculated based on comparing
the Ct values of the standard curve generated from 10-fold dilutions of telomerase
control oligo with known copy numbers of the telomeric repeats.
In vitro differentiation. piPS and piPC were derived from in vitro spontaneous
differentiation assay through EBs formation as described byMiyoshi and colleagues14.
Briefly, iPS and iPC cells were differentiated into EBs following the floating culture
technique in ultra-low attachment plates (Corning) in the absence of bFGF for 8 days.
EBs were collected at day 8 and analyzed for markers of the three embryonic germ
layers. After 8 days of floating culture, EBs were then transferred to a gelatin-coated
plate and cultured in the same medium for another 8 days to allow the attachment of
the EBs.
Gene expression profiling. The quality of total RNA of our samples was evaluated
usingAgilent 2100 Bioanalyzer (Agilent Technologies). For gene expression profiling,
biotinylated antisense RNA of each sample was amplified using Illumina TotalPrep
RNAAmplification Kit (Ambion), and hybridized onto HumanHT-12 v4 Expression
BeadChip (Illumina) as per manufacturer’s instruction. Raw data (with background
subtraction) was exported using Bead Studio (Illumina) and analyzed using LUMI50
and LIMMA51, which were executed in R statistical software52. The microarray data
was normalized using the quantile method53. All spots that were considered
background were coerced to the maxima of background signal. The processed data
was then used to generate the hierarchical clustering of samples as well as pair-wise
comparison using 2-sample t-test and inference made through empirical Bayesian.
Genes that were differentially regulated must fulfill two criteria:$2-fold change and
FDR-adjusted P-value (FDR) #0.05.
Genome-wide DNA methylation profiling. Genomic DNA was extracted using the
DNeasy Blood and Tissue Kit (Qiagen), and bisulfite-treated using the EZ DNA
Methylation Kit (Zymo Research), as per the instructions in the kit. Bisulfite-treated
DNAwas amplified and hybridized to the InfiniumHumanMethylation27 BeadChip
(Illumina), in accordance with the manufacturer’s recommendations. The chips were
scanned and the raw intensities for both methylated and unmethylated DNA were
exported using Genome Studio (Illumina). The microarray data was analyzed using
methyLUMI50 and LIMMA51 executed on R software52. The two-color channel data
was preprocessed separately. The intensity signal was background subtracted before
normalizing by the quantile method53. This is followed by coercing all negative values
to 0. The processed data were used to generate hierarchical clustering as well as theM-
value and b-value. Each interrogated locus was probed by amethylated-specific probe
(Met) and an unmethylated-specific probe (Unmet). We represent the degree of
methylation using the M-value and b-value. The M-value5log2(Met/Unmet) while
the b-value5Met/(Unmet1Met)54. M-value was utilized for statistical testing while
b-value was used for a more intuitive interpretation of the degree of methylation. We
categorized b-value as methylated if b-valueg(0.8, 1.0], partially methylated if
b-valueg[0.2, 0.8] and unmethylated ifb-valueg[0, 0.2).We declare a promoter was
methylated if at least half the probes have b-value$0.2; a promoter was claimed
hypermethylated if at least half the probes were in higher methylation category
compared to the reference (i.e. from unmethylated to partially methylated or
methylated) and if FDR#0.05 (calculated using M-values). Hypomethylated was the
reverse. All hypomethylated promoters in iPC compared to cancer parents were
analyzed using Database for Annotation, Visualization and Integrated Discovery
(DAVID)55,56 by ‘Gene Ontology biological process’ enrichment.
Gene set analysis. Four sets of genes were generated i.e. aberrantly methylated
promoters (AMP), commonly upregulated genes in NSCLC (UR), oncogenes (OG)
and tumor suppressors (TS). AMP was generated by literature search. UR was
generated by literature search as well as using a data set from GSE19188 (taken from
GEO database)22. OG and TS were obtained from the Memorial Sloan-Kettering
Cancer Center28.
Methylation-specific PCR assay. 1 mL bisulfite-treated DNAwas amplified using the
methylation-specific PCR primers designed using MethPrimer. All primer sequences
were supplied in Table S7. For each PCR reaction, a total of 25 mL reaction volume
contained 1 mM forward and reverse primers, as well as HotStarTaq Plus Master Mix
(Qiagen). PCR products were resolved by agarose gel electrophoresis and stainedwith
ethidium bromide. The bands were scored as methylated or unmethylated according
to the presence or absence of a PCR product respectively.
Immunofluorescence staining. For immunofluorescence assay, cells were first fixed
with 4% paraformaldehyde for 15 minutes followed by permeabilization step for 10
minutes with 0.5% NP-40 in PBS. The cells were then blocked with 5% BSA for one
hour and incubated with primary antibodies for overnight, and later followed with
fluorescence-conjugated secondary antibodies for an hour. Primary antibodies used
in this assay include TRA-1-60 (Cell Signaling) and Nanog (Cell Signaling). All
images were captured using Olympus Fluoview FV1000 microscope and one
representative image of at least three repeats/triplicates is shown in results section.
Bisulfite sequencing. 3 mL bisulfite-treated DNA was amplified and for each PCR
reaction, 0.5 mM forward and reverse primers, HotStarTaq PlusMaster Mix (Qiagen)
were used in a 50-mL total reaction volume. The PCR cycles were as follows: initial
denaturation at 95uC for 10 minutes; 37 cycles of 30 seconds at 94uC, 30 seconds at
55uC and 60 seconds at 72uC; followed by a final extension for 10 minutes at 72uC.
The PCR products were purified with QIAquick column (Qiagen) before subcloning
into pGEM-T vector (Promega). The ligation reactions were transformed into JM109
competent cells (Promega), as described in kit procedures, and blue/white screening
was used to randomly select a minimum of ten bacterial clones. Plasmid DNA was
then isolated from each clone using QIAprep Miniprep Kit (Qiagen). Clones were
further screened by amplifying with universal primers (T7 and SP6) and were
resolved by agarose gel electrophoresis to verify insert and plasmid size. Four clones of
each sample were verified by sequencing with the T7 promoter universal primers.
Accession number. All microarray gene expression and methylation data have been
deposited at NCBI GEO database under accession number GSE35913.
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